Advanced Endometrial Cancer: Treatment Optimization - Episode 10

Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

December 22, 2022

Courtney R. Arn, APRN-CNP, Kimberly Halla, NP, Kathleen Lutz, RN, NP-BC WH, Kimberly A. Spickes, CNP

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer

EP. 2: Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer

EP. 3: Currently Available Treatment Modalities in Endometrial Cancer

EP. 4: First-Line Treatments for Patients With Advanced Endometrial Cancer Who Are Unfit for Surgery

EP. 5: Common Adverse Events Seen With Chemotherapy for Advanced Endometrial Cancer

EP. 6: Efficacy of Chemotherapy in Patients with Advanced Endometrial Cancer

EP. 7: Treatment Options for Patients with Recurrent Endometrial Cancer

EP. 8: Educating Patients With Endometrial Cancer on Treatment-Related Adverse Events

EP. 9: Monitoring Patients on Therapy for Recurrent Endometrial Cancer

Now Viewing

EP. 10: Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer

EP. 11: Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

EP. 12: Discussing Dose Reductions and Interruptions with Patients on Therapy for Endometrial Cancer

EP. 13: Greatest Unmet Needs for Patients with Endometrial Cancer

EP. 14: Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer